NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Monday that its preliminary first quarter revenues would be in the range of $11.4 million to $11.6 million, up 73 percent to 76 percent, respectively, from $6.6 million in Q1 2016.

Also on Monday, the firm received a notification letter from Nasdaq stating that it is out of compliance with a rule requiring timely filing of periodic reports with the US Securities and Exchange Commission. The firm received the notice because it had not filed its Form 10-Q for Q1 in the required time.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.